PROGRAM |
DISCIPLINE |
HEALTH THEMES |
|
|---|---|---|---|
| Disease Elimination | Life Sciences | Malaria |
Immunity to malaria is slow to develop due to the rapid induction of regulatory cell responses that hamper adaptive immunity. Type I IFN signalling is key to these regulatory cell responses. In a world’s first Phase 1b clinical trial, we tested whether Ruxolitinib, a JAK1/2 inhibitor, could block Type I IFN signalling and improve protective immunity to malaria in humans.
This project will use human clinical samples collected during Phase 1b clinical trial to understand the impact of Type I IFN signalling blockade on protective immune development in humans. You will learn to apply advanced immunology techniques (for example multiparametric flow cytometry, RNAseq, multiomic analysis), and analyse data using bioinformatic pipelines, and advanced statistical methods.
Understanding immune development in this unique clinical trial will allow researchers to develop approaches to boost protective immunity to malaria, leading to novel therapeutics in the future.
Contact
Dr Michelle Boyle
Head, Cellular Responses to Disease and Vaccination Group
michelle.boyle@burnet.edu.au
More Student Projects
burnet.edu.au/studentprojects
View projects
Why study at Burnet?
When you study at Burnet, you broaden your impact working across our three Institute-wide programs: Disease Elimination; Health Security and Pandemic Preparedness; Maternal, Child and Adolescent Health.
Train with internationally recognised experts in a structured student support system, and gain a holistic research experience along the way.
Find out more Student Projects